Photodynamic tumor eradication with a novel targetable photosensitizer: Strong vascular effects and dependence on treatment repetition versus potentiation

Photochemistry and Photobiology

Volumn 89, Issue 3, 2013, Pages 687-697

  Savellano, Mark D ^a   Owusu Brackett, Nicci ^a,b   Son, Ji ^a   Ganga, Tanay ^a   Leung, Nadia L ^a   Savellano, Dagmar H ^a,c  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AC SPPP COMPOUND; AC-SPPP COMPOUND; ANTIBODY CONJUGATE; CETUXIMAB; DIPEPTIDE; DOXORUBICIN; FLUORESCENT DYE; MONOCLONAL ANTIBODY; PHOTOSENSITIZING AGENT; PORPHYRIN;

ANIMAL; ARTICLE; CANCER TRANSPLANTATION; CHEMISTRY; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; FEMALE; FLUORESCENCE IMAGING; HUMAN; LIGHT; MOUSE; NUDE MOUSE; PATHOLOGY; PHOTOCHEMOTHERAPY; SQUAMOUS CELL CARCINOMA; SYNTHESIS; TUMOR CELL LINE; TUMOR VOLUME; VASCULARIZATION; VULVA TUMOR;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DIPEPTIDES; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FLUORESCENT DYES; HUMANS; IMMUNOCONJUGATES; LIGHT; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OPTICAL IMAGING; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; TUMOR BURDEN; VULVAR NEOPLASMS;

MUS MUSCULUS;

EID: 84876789485     PISSN: 00318655     EISSN: 17511097     Source Type: Journal    
DOI: 10.1111/php.12018     Document Type: Article

References (32)

1. Goldstein, N. I., M. Prewett, K. Zuklys, P. Rockwell, and, J. Mendelsohn, (1995) Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res. 1, 1311-1318.
2. Viloria-Petit, A., T. Crombet, S. Jothy, D. Hicklin, P. Bohlen, J. M. Schlaeppi, J. Rak, and, R. S. Kerbel, (2001) Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis. Cancer Res. 61, 5090-5101.
3. Abu-Yousif, A. O., A. C. Moor, X. Zheng, M. D. Savellano, W. Yu, P. K. Selbo, and, T. Hasan, (2012) Epidermal growth factor receptor-targeted photosensitizer selectively inhibits EGFR signaling and induces targeted phototoxicity in ovarian cancer cells. Cancer Lett. 321, 120-127.
4. Savellano, M. D., and, T. Hasan, (2003) Targeting cells that overexpress the epidermal growth factor receptor with polyethylene glycolated BPD verteporfin photosensitizer immunoconjugates. Photochem. Photobiol. 77, 431-439.
5. Savellano, M. D., and, T. Hasan, (2005) Photochemical targeting of epidermal growth factor receptor: A mechanistic study. Clin. Cancer Res. 11, 1658-1668.
6. Savellano, M. D., B. W. Pogue, P. J. Hoopes, E. S. Vitetta, and, K. D. Paulsen, (2005) Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide-a immunoconjugates. Cancer Res. 65, 6371-6379.
7. Snyder, J. W., W. R. Greco, D. A. Bellnier, L. Vaughan, and, B. W. Henderson, (2003) Photodynamic therapy: A means to enhanced drug delivery to tumors. Cancer Res. 63, 8126-8131.
8. Veldman, R. J., G. A. Koning, A. van Hell, S. Zerp, S. R. Vink, G. Storm, M. Verheij, and, W. J. van Blitterswijk, (2005) Coformulated N-octanoyl-glucosylceramide improves cellular delivery and cytotoxicity of liposomal doxorubicin. J. Pharmacol. Exp. Ther. 315, 704-710.
9. Mamot, C., R. Ritschard, A. Wicki, W. Kung, J. Schuller, R. Herrmann, and, C. Rochlitz, (2012) Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells. J. Drug Target. 20, 422-432.
10. Deonarain, M., I. Stamati, and, G. Yahioglu, (2012) Antibody-targeted photodynamic therapy. In Molecular and Cellular Therapeutics (Edited by, D. Whitehouse, and, R. Rapley,), pp. 103-124. John Wiley & Sons, Ltd., Chichester, West Sussex, UK.
11. Sharman, W. M., J. E. van Lier, and, C. M. Allen, (2004) Targeted photodynamic therapy via receptor mediated delivery systems. Adv. Drug Deliv. Rev. 56, 53-76.
12. Hsu, C. Y., P. S. Lai, C. L. Pai, M. J. Shieh, N. Nishiyama, K. Kataoka, C. T. Lim, and, J. C. H. Goh, (2009) Enhanced cytotoxicity of doxorubicin by micellar photosensitizer-mediated photochemical internalization in drug-resistant MCF-7 Cells. In 13th International Conference on Biomedical Engineering (Edited by, R. Magjarevic,), pp. 1451-1454. Springer, Berlin, Germany.
13. Cheng, C., Y. Wang, A. Haouala, E. Debefve, S. Andrejevic Blant, T. Krueger, M. Gonzalez, J. P. Ballini, S. Peters, L. Decosterd, H. van den Bergh, H. B. Ris, and, J. Y. Perentes, (2011) Photodynamic therapy enhances liposomal doxorubicin distribution in tumors during isolated perfusion of rodent lungs. Eur. Surg. Res. 47, 196-204.
14. Wang, Y., M. Gonzalez, C. Cheng, A. Haouala, T. Krueger, S. Peters, L. A. Decosterd, H. van den Bergh, J. Y. Perentes, H. B. Ris, I. Letovanec, and, E. Debefve, (2012) Photodynamic induced uptake of liposomal doxorubicin to rat lung tumors parallels tumor vascular density. Lasers Surg. Med. 44, 318-324.
15. Ferrario, A., and, C. J. Gomer, (1990) Systemic toxicity in mice induced by localized porphyrin photodynamic therapy. Cancer Res. 50, 539-543.
16. Pekkola-Heino, K., J. Kulmala, S. Grenman, T. E. Carey, and, R. Grenman, (1989) Radiation response of vulvar squamous cell carcinoma (UM-SCV-1A, UM-SCV-1B, UM-SCV-2, and A-431) cells in vitro. Cancer Res. 49, 4876-4878.
17. Savellano, M. D., N. Owusu-Brackett, J. Son, T. Callier, and, D. H. Savellano, (2010) Development of an ErbB-overexpressing A-431 optical reporting tumor xenograft model to assess targeted photodynamic therapy regimens. Photochem. Photobiol. 86, 1379-1389.
18. Ogura, H., T. Kobayashi, K. Shimizu, K. Kawabe, and, K. Takeda, (1979) Novel active ester synthesis reagent (N,N'-disuccinimidyl carbonate). Tetrahedron Lett. 20, 4745-4746.
19. Bellnier, D. A., B. W. Henderson, R. K. Pandey, W. R. Potter, and, T. J. Dougherty, (1993) Murine pharmacokinetics and antitumor efficacy of the photodynamic sensitizer 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a. J. Photochem. Photobiol., B 20, 55-61.
20. Bellnier, D. A., W. R. Greco, G. M. Loewen, H. Nava, A. R. Oseroff, R. K. Pandey, T. Tsuchida, and, T. J. Dougherty, (2003) Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients. Cancer Res. 63, 1806-1813.
21. Haigler, H., J. F. Ash, S. J. Singer, and, S. Cohen, (1978) Visualization by fluorescence of the binding and internalization of epidermal growth factor in human carcinoma cells A-431. Proc Natl Acad Sci U S A 75, 3317-3321.
22. Anido, J., P. Matar, J. Albanell, M. Guzman, F. Rojo, J. Arribas, S. Averbuch, and, J. Baselga, (2003) ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin. Cancer Res. 9, 1274-1283.
23. Shepard, H. M., G. D. Lewis, J. C. Sarup, B. M. Fendly, D. Maneval, J. Mordenti, I. Figari, C. E. Kotts, M. A. Palladino Jr, A. Ullrich, and, D. Slamon, (1991) Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic. J. Clin. Immunol. 11, 117-127.
24. Matsumura, Y., and, H. Maeda, (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46, 6387-6392.
25. Moghimi, S. M., A. C. Hunter, and, J. C. Murray, (2001) Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacol. Rev. 53, 283-318.
26. Gabizon, A., R. Catane, B. Uziely, B. Kaufman, T. Safra, R. Cohen, F. Martin, A. Huang, and, Y. Barenholz, (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 54, 987-992.
27. Fleshker, S., D. Preise, V. Kalchenko, A. Scherz, and, Y. Salomon, (2008) Prompt assessment of WST11-VTP outcome using luciferase transfected tumors enables second treatment and increase in overall therapeutic rate. Photochem. Photobiol. 84, 1231-1237.
28. Bhatti, M., G. Yahioglu, L. R. Milgrom, M. Garcia-Maya, K. A. Chester, and, M. P. Deonarain, (2008) Targeted photodynamic therapy with multiply-loaded recombinant antibody fragments. Int. J. Cancer 122, 1155-1163.
29. Castellani, A., G. P. Pace, and, M. Concioli, (1963) Photodynamic effect of haematoporphyrin on blood microcirculation. J Pathol Bacteriol 86, 99-102.
30. Chapman, J. D., M. S. McPhee, N. Walz, M. P. Chetner, C. C. Stobbe, K. Soderlind, M. Arnfield, B. E. Meeker, L. Trimble, and, P. S. Allen, (1991) Nuclear magnetic resonance spectroscopy and sensitizer-adduct measurements of photodynamic therapy-induced ischemia in solid tumors. J. Natl Cancer Inst. 83, 1650-1659.
31. Palumbo, A., F. Hauler, P. Dziunycz, K. Schwager, A. Soltermann, F. Pretto, C. Alonso, G. F. Hofbauer, R. W. Boyle, and, D. Neri, (2011) A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels. Br. J. Cancer 104, 1106-1115.
32. Minn, A. J., G. P. Gupta, P. M. Siegel, P. D. Bos, W. Shu, D. D. Giri, A. Viale, A. B. Olshen, W. L. Gerald, and, J. Massague, (2005) Genes that mediate breast cancer metastasis to lung. Nature 436, 518-524.